| Revenue Growth | Sleep grew 4%; Diabetes declined 3%; Respiratory fell 6.5%; Wound fell 6%. |
|---|---|
| Mgmt Confidence | CEO expressed optimism for turnaround but acknowledged significant 2026 underperformance. |
| Margin Trends | Cost of revenue 56.6%, up 280bps; SG&A 41.5%, up from 38.1%. |
| Op. Leverage | Challenges taking out enough cost to offset lost revenue from payer loss. |
| Pricing Power | Contractual allowances $6M unfavorable; supplier price increases noted as not significant. |
| Vol vs Price | Growth constrained by high friction at intake and poor patient retention. |
| Segment Growth | Sleep supplies drove growth; CGM and respiratory categories saw ongoing declines. |
| Capex & Debt | Net debt $1.73B; $35M YTD capex related to former large payer. |
| Regulatory | Prepaid audits from large commercial payers largely resolved; passed with flying colors. |
| Commentary | Focusing on 'speed to value' through a multi-year value creation plan. |
| New Launches | Launching revamped branch and back office operations in Q1 2027. |
Growth
Revenue $602M, down 1% excluding payer loss; Sleep grew 4%, Respiratory fell 6.5%.
Outlook
Full-year revenue guided to bottom of $2.45B-$2.55B range; 2027 outlook expected early next year.
Risks
Management pivoted on liquidity bridge specifics; EBITDA guidance cut by 30% from $310M midpoint.
The company's earnings call, NYSE: ACH, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Accendra Health Inc: key numbers
- Share price
- $0.0857Close, Nov 16
- Market cap
- $6.59M
- Shares outstanding
- 76.92MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Medical, Dental & Hospital Equipment & SuppliesSIC 5047
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Accendra Health Inc
All →Accendra Health Q3 2026 Results: Net Loss of $19.7M, Loss Narrows
Accendra Health reported a net loss of $19.7 million for the third quarter of 2026, a significant improvement from the $150.3 million loss in the prior year period. Total net revenue declined to $601.8 million from $697.3 million, while the company's total deficit increased to $568.2 million as of September 30, 2026.
- Key figure
- Net loss $19.7M
Accendra Health Financial Results
Accendra Health reported third quarter 2026 net revenue of $601.8 million and a GAAP net loss from continuing operations of $18.0 million. CEO Kenny Gardner-Smith noted that 2026 results have fallen short of expectations and announced the development of a value creation plan to return the business to profitability.
- Term
- Q3 2026
“It is equally clear to me that our results to date in 2026 have fallen well short of our expectations and potential. We have identified four key areas which are critical to our continued transformation and returning the business to the kind of profitability that our shareholders should expect”
Kenny Gardner-Smith, President & Chief Executive Officer
“We are already taking action on our turnaround, and, over the next several months, we will have our value creation plan fully underway. The value creation plan is the cornerstone of returning the business to its potential, and we look forward to sharing details with all stakeholders in the coming months”
Kenny Gardner-Smith, President & Chief Executive Officer
Accendra Health Leadership Change
Perry A. Bernocchi will step down as Executive Vice President and Chief Operating Officer of Accendra Health, effective October 29, 2026. He will transition to a role as Strategic Advisor to the CEO through December 31, 2026, maintaining his current base salary and 2026 bonus eligibility during the transition period.
- Term
- through Dec 31, 2026
Accendra Health $150M Debt Financing with PNC Bank, National Association
Accendra Health's subsidiaries entered into an amendment to their Receivables Purchase Agreement with PNC Bank, extending the $150 million facility's termination date to October 2029. The amendment also revises account control provisions and reporting obligations while maintaining the existing facility size to ensure liquidity. The program is backed by the company's accounts receivable portfolio through its Accendra Funding and Byram Healthcare units.
- Value
- $150M
- Counterparty
- PNC Bank, National Association
- Term
- through Oct 2029
Accendra Health Nasdaq/NYSE Compliance Notice
Accendra Health received a deficiency notice from the NYSE for failing to maintain an average market capitalization and stockholders' equity of at least $50.0 million. The company has 45 days to submit a business plan to regain compliance within 18 months and its stock will continue to trade on the exchange during this period.
- Counterparty
- New York Stock Exchange
- Term
- 18 months
Accendra Health Nasdaq/NYSE Compliance Notice
Accendra Health received a deficiency notice from the NYSE on October 6, 2026, because its common stock average closing price fell below $1.00 over a 30 trading-day period. The company has six months to regain compliance and is considering alternatives including a potential reverse stock split. The notice does not immediately impact the listing or the company's business operations.
- Counterparty
- New York Stock Exchange
- Term
- 6 months